For information on CSL Behring COVID-19 updates, please click here

Why choose Hizentra for PI therapy?

Infusion schedule icon PI

Choose when and where you infuse

Self-administration with Hizentra means you and your doctor can decide where you can infuse. Flexible dosing options (from daily to once every 2 weeks) mean you won’t have to adjust or cancel your plans due to IV infusion appointments.

No vein infusion icon PI

No more IV infusions

IV infusions can be challenging for people who have hard-to-find or damaged veins. Hizentra allows you to infuse just under the skin, not into a vein, after training from your doctor.

Safety icon PI

Proven safety

Hizentra has an established safety profile and demonstrated tolerability. In clinical trials, the most common side effects were redness, swelling, itching, and/or bruising at the infusion site; headache; chest, joint or back pain; diarrhea; tiredness; cough; rash; itching; fever, nausea, and vomiting. These are not the only side effects possible.

Real Hizentra experience in PI

Real Hizentra experience in PI


  • Mother and yoga/cycle instructor
  • Diagnosed with PI at age 32
  • Living a more convenient life
Watch Video

Hizentra gives you proven protection

Hizentra maintains steady Ig levels*†

Steady Ig Levels chart

*Comparison of average IgG concentrations with 10% IVIg and 20% under-the-skin Ig. Average Ig levels measured at weeks 8–16 in the 20% Ig study are compared with average levels measured before and after the 7th infusion for patients with a 4-week schedule in the 10% Ig study (data from 24 or 25 patients were available for all data points except day 28, when data were available for 21 patients). Average 20% Ig dose was 202.3 mg/kg body weight; average 10% Ig dose was 156.1 mg/kg body weight. No difference in the benefit of Ig blood levels for under-the-skin vs IV infusions has been shown by substantial study results or experience.

Reproduced from Wasserman RL, Melamed I, Nelson RP Jr. et al. Pharmacokinetics of subcutaneous Ig Pro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011 ;50(6):405-414. With permission of Springer. The weekly dose of Hizentra was 1.53 times that of the previous weekly equivalent dose of IVIg.

You are now leaving the current website.

Do you want to continue?

No Yes